TAG:
pathology market
New Cytology Technology Entering Study Phase
By Robert Michel | From the Volume VIII No. 5 – April 9, 2001 Issue
CEO SUMMARY: There’s a new contestant in the ongoing battle to win the Pap smear technology wars. Ampersand Medical Corporation, by signing a strategic alliance with AmeriPath, Inc., has signaled that it’s ready to bring its technology to market. AmeriPath will play a major role in ex…
“Local” Anatomic Path Has Two Major Players
By Robert Michel | From the Volume VIII No. 2 – February 5, 2001 Issue
CEO SUMMARY: After a lot of money and much effort, the fledgling crop of companies wanting to consolidate and manage pathology group practices has narrowed into just two market leaders: AmeriPath and Pathology Service Associates. These two companies could not be more different in their go…
Lab Sales & Marketing Programs Are Changing
By Robert Michel | From the Volume VIII No. 2 – February 5, 2001 Issue
CEO SUMMARY: Market evidence points to a shifting role in the sales priorities of the national labs. Meanwhile, regional laboratories and pathology companies are enjoying surprising success with their sales and marketing programs. These shifting patterns may indicate a new stratification …
Competitive Dynamics In the Laboratory Testing Marketplace
By Robert Michel | From the Volume VII No. 18 – December 25, 2000 Issue
This section of the White Paper deals with the marketplace for laboratory services. For brevity and clarity, I will address five components: 1) independent commercial laboratories; 2) hospital-based laboratories; 3) esoteric, reference, and specialty testing laboratories; 4) anatomic pathology lab- o…
AmeriPath Will Acquire Inform DX for $44.6 Mil
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: It’s another example of consolidation in the anatomic pathology marketplace. AmeriPath, Inc.’s acquisition of Inform DX, Inc. positions the company to do as much as $350 million in revenues next year. By acquiring Inform DX, AmeriPath also gains entry into six more states…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
AmeriPath Pursues Ambitious Strategy Of Rapid Expansion
By Robert Michel | From the Volume VII No. 4 – March 6, 2000 Issue
CEO SUMMARY: As the pathology profession’s only publicly-traded physician practice management company, AmeriPath is the spear point of far-reaching changes now transforming pathology. With an annual revenue run rate of $270 million and an ample war chest of growth capital, AmeriPath int…
Single-Specialty Path PPMs Posting Strong Growth, Profits
By Robert Michel | From the Volume VII No. 3 – February 14, 2000 Issue
CEO SUMMARY: Although the financial travails of the physician practice management (PPM) industry are widely known, there is little recognition that a number of single-specialty PPMs are doing well. This is true of pathology, where at least six pathology-based PPMs still remain in business…
Don’t Take Your Eyes Off the Ball!
By R. Lewis Dark | From the Volume VI No. 12 – August 30, 1999 Issue
HOW MANY OF US HAD A FATHER WHO TAUGHT US THE BASICS OF BASEBALL almost as soon as we learned to walk? I can still remember my father repeatedly advising me “don’t take your eyes off the ball!” With the recent merger of Quest Diagnostics Incorporated and SmithKline Bee…
Associated Pathologists Laboratories, Dynacare, Bio-Reference Labs, Quest, AmeriPath
By Robert Michel | From the Volume VI No. 9 – June 28, 1999 Issue
ASSOCIATED PATH LABS WINS PATENT FOR DRUGS OF ABUSE TEST IT’S NOT TOO OFTEN that independent commercial laboratories are awarded patents. Las Vegas-based Associated Pathologists Laboratories received a patent for a technique it developed relating to drugs of abuse testing….
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized